Discounted for Persistent Weakness, Not Missed Potential
Evotec trades at a discount for good reason. Negative EBITDA and a 17% drop in Biologics revenue point to ongoing weakness. The market sees a risk case, not a turnaround. Cheap isn’t the same as overlooked.
Published by AssetNext · 2026-07-19
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-24 | Profile and price weak | 17 | -53.6% | -34.4% |
| 2026-07-17 | Profile and price weak | 16 | -53.8% | -30.4% |
Break down EVT.DE's structural position across all peer dimensions with the interactive app.